Procept Biorobotics Showcases Aquablation Therapy as Next-Generation BPH Solution in Investor Presentation

Procept Biorobotics Corporation has unveiled an investor presentation emphasizing its Aquablation Therapy as a next-generation solution for benign prostatic hyperplasia (BPH). This automated waterjet technology aims to cater to various prostate sizes while enhancing safety and efficacy compared to traditional surgical methods. The presentation highlights a significant market opportunity, with over 8 million patients treated and a U.S. surgical market exceeding $20 billion. It also critiques pharmaceutical therapies for their limited symptom relief and potential side effects.

Robotics Stocks To Watch Today - November 9th

Teradyne, PROCEPT BioRobotics, Serve Robotics, Richtech Robotics, and Ouster are highlighted as key robotics stocks to watch today, according to MarketBeat. These companies are involved in various aspects of robotics and automation, including manufacturing, surgical solutions, and delivery services. Teradyne is noted for its automated test systems, while PROCEPT focuses on surgical robotics for urology. Serve Robotics specializes in food delivery robots, Richtech Robotics offers automation solutions for the service industry, and Ouster provides lidar sensors for multiple sectors. Investors view these stocks as growth-oriented within a cyclical market.

PROCEPT BioRobotics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 83.33 M

Morgan Stanley Remains a Buy on PROCEPT BioRobotics (PRCT)

According to TipRanks, Wood is an analyst with an average return of -0.5% and a 52.90% success rate. Wood covers the Healthcare sector, focusing on stocks such as Becton Dickinson, Medtronic, and Zimmer Biomet Holdings. In addition to Morgan Stanley, PROCEPT BioRobotics also received a Buy from Wells Fargo’s Nathan Treybeck in a report issued today. However, on the same day, BTIG maintained a Hold rating on PROCEPT BioRobotics (NASDAQ: PRCT).

PROCEPT BioRobotics: Hold Rating Amid Strong Revenue but Concerns Over Utilization and Sales Cycles

Ryan Zimmerman has assigned a Hold rating to PROCEPT BioRobotics, citing strong revenue growth but concerns over handpiece utilization and declining average selling prices. The new CEO emphasizes the need for improved utilization, while management's comments on longer sales cycles and inventory adjustments have led to a cautious outlook. Preliminary revenue guidance suggests potential downward adjustments to estimates. Despite a decrease in valuation, concerns about slowing utilization and high expectations persist, prompting the Hold rating. TR | OpenAI – 4o also reiterated a Hold rating with a $35.00 price target.